AE adds new trials to its Clinical Trials Watch


Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date and accessible information on clinical trials that are investigating drugs for Alzheimer’s disease (AD) and/or dementia. In addition to providing information on phase II and III clinical trials recruiting participants in Europe, the database has been extended and includes also trials of devices, neurostimulation, cognitive training and behavioral interventions.

In January 2023, eight new clinical trials have been added to the service:

• Phase II trial evaluating the effectiveness of non-invasive transcutaneous electrical stimulation procedure in decreasing a long-term forgetting in people with amnestic mild cognitive impairment (University of Dublin, Trinity College).

• Phase II trial evaluating the efficacy and safety of oral tablets of masupirdine for the treatment of agitation in people with dementia of the Alzheimer’s type (Suven Life Sciences Limited).

• ADvance II trial evaluating the safety and efficacy of Deep Brain Stimulation of the fornix (specific area of the brain) in people with mild probable AD (Functional Neuromodulation Ltd).

• ALMUTH trial evaluating the effects of music lessons on brain plasticity, mood and quality of life in people with AD (University of Bergen).

• Trial evaluating if computerised-cognitive training is able to attenuate cognitive decline related to AD (University of Bern).

• Trial evaluating whether repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in people with neurodegenerative diseases, including dementia with Lewy Bodies, AD and Frontotemporal dementia (Kuopio University Hospital).

• Trial investigating the effectiveness of mental imagery in motor and cognitive rehabilitation in people with early stage of dementia (University of West Attica).

• N-DOSE AD trial evaluating the safety and determining the optimal dose of nicotinamide riboside in people with AD (Haukeland University Hospital).

Further information about the CTW is available on: